Membership benefits

Early Access

to latest news and research articles
Members have free and unrestricted access to papers immediately after publication

Members' Services

CES offers free or discounted access to several platforms
Journal subscriptions, publication fees, annual meetings, reagents from industry partners, job postings & more


Eligibility for the Cancer Epigenetics Society Awards
Members can exclusively nominate and be recipients of the Epi Awards

Members' Resources

CES offers several resources to scientists & patients
Several cancer epigenetics databases, meetings, grant & job listings, and continuously expanding resources for scientists & patients

Our databases & journals

Our latest video

The latest news from CES databases & journals

01/09/2017- Dr. Tatiana Kutateladze, Professor of Pharmacology at the University of Colorado School of Medicine (Aurora, CO, USA) is Editor at Cancer Epigenetics
12/21/2016-Dr. Luciano Di Croce, Head of Epigenetics Events in Cancer Group at the Centre for Genomic Regulation (CGR) at the Barcelona Institute of Science and Technology (Barcelona, Spain) is Editor at Cancer Epigenetics
12/15/2016-Cancer Epigenetics Drug Database now includes four families of epigenetic-targeting drugs
12/9/2016-Dr. Giacomo Cavalli, Head of Chromatin & Cell Biology Laboratory, Institute for Human Genetics (Montpellier, France) & member of the EpigeneSys Network of Excellence, is Editor at Cancer Epigenetics
11/28/2016-Dr. Jonathan D. Licht, Director of University Florida Health Cancer Center, Gainesville (FL, USA) & Dana-Farber SPORE in Myeloma Investigator, is Editor at Cancer Epigenetics

Latest Scientific Cancer Epigenetics News

Latest Medical Cancer Epigenetics News

FDA approves first colorectal cancer screening blood test: the first blood test to detect colorectal cancer approved by the US Food and Drug Administration (FDA) is a cancer epigenetics diagnostic test developed by Epigenomics AG, a German medical diagnostics company that specializes in colorectal and lung cancers. The test detects DNA methylation of Septin 9 (SEPT9), a gene on chromosome 17 whose product controls cytokinesis and cell cycle, which may serve as a tumor suppressor in ovarian cancer, and which is associated to colorectal cancer. The cancer epigenetics diagnostic test offers a minimally invasive alternative to patients who may not be comfortable undergoing a colonoscopy. The diagnostic kit dubbed Epi proColon® was already approved for use in Argentina, China, Europe, and Hong Kong (Cancer Epigenetics Society; medical news).

The Cancer Epigenetics Society in numbers

Society Members:

Continents covered
Affiliate Members
Biomedical MD/PhD Students
Biomedical MD/PhDs

Latest Cancer Epigenetics Society members

Hanna Kryh Öberg (Postdoctoral Fellow), Tygelsjö, Sweden
Vincenzo Di Cerbo (Postdoctoral Fellow), Dept of Biochemistry, Oxford University, Oxfordshire, Oxford, UK
Angel Diaz-Lagares (Researcher), Cancer Epigenomics Laboratory, Translational Medical Oncology Group, Health Research Institute of Santiago, Galicia, Spain
Michaela Schwaiger (Computational Scientist), Novartis Institutes for Biomedical Research, Basel, Switzerland
Rachael Reynolds (Student), Athlone Institute of Technology, Athlone, Co. Westmeath, Ireland
Roshan Kumar Singh (PhD Student), University of Delhi, Delhi, India
Payel Sen (Postdoctoral Fellow), Epigenetics Program, Department of Cell and Developmental Biology, University of Pennsylvania, Philadelphia, USA
Raju Kandimalla (Postdoctoral Fellow), Center for Gastrointestinal Research & Center for Epigenetics, Cancer Prevention & Genomics, Baylor University Medical Center, Dallas, TX, USA

Society Web Portal Contents:

Research grants
Epigenetic modifiers
Scientific meetings
Epigenetics drugs
Advocacy & Support groups
Cancers & other neoplasms
Cancer epigenetics clinical trials
Cancer cell lines
Cancer epigenetics experiments